ZA200109839B - Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists. - Google Patents

Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists.

Info

Publication number
ZA200109839B
ZA200109839B ZA200109839A ZA200109839A ZA200109839B ZA 200109839 B ZA200109839 B ZA 200109839B ZA 200109839 A ZA200109839 A ZA 200109839A ZA 200109839 A ZA200109839 A ZA 200109839A ZA 200109839 B ZA200109839 B ZA 200109839B
Authority
ZA
South Africa
Prior art keywords
benzhydryl
azabicyclo
polymorphs
methoxybenzyl
oct
Prior art date
Application number
ZA200109839A
Other languages
English (en)
Inventor
Massett Stephen Sargent
Quallich George Joseph
Rose Peter Robert
Wint Lewin Theophilus
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200109839B publication Critical patent/ZA200109839B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200109839A 1999-06-01 2001-11-29 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists. ZA200109839B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13699599P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
ZA200109839B true ZA200109839B (en) 2003-01-29

Family

ID=22475353

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109839A ZA200109839B (en) 1999-06-01 2001-11-29 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists.

Country Status (38)

Country Link
US (1) US6387925B1 (es)
EP (1) EP1181289A1 (es)
JP (1) JP2003501353A (es)
KR (1) KR20020005055A (es)
CN (1) CN1353712A (es)
AP (1) AP2001002350A0 (es)
AR (1) AR029753A1 (es)
AU (1) AU767331B2 (es)
BG (1) BG106139A (es)
BR (1) BR0011125A (es)
CA (1) CA2372236A1 (es)
CO (1) CO5170468A1 (es)
CR (1) CR6513A (es)
CZ (1) CZ20014270A3 (es)
DZ (1) DZ3051A1 (es)
EA (1) EA004206B1 (es)
EE (1) EE200100655A (es)
GT (1) GT200000086A (es)
HK (1) HK1046407A1 (es)
HN (1) HN2000000076A (es)
HR (1) HRP20010884A2 (es)
HU (1) HUP0201798A3 (es)
IL (1) IL145952A0 (es)
IS (1) IS6129A (es)
MX (1) MXPA01012328A (es)
NO (1) NO20015845L (es)
NZ (1) NZ514762A (es)
OA (1) OA11955A (es)
PA (1) PA8496001A1 (es)
PE (1) PE20010155A1 (es)
PL (1) PL352715A1 (es)
SK (1) SK17342001A3 (es)
SV (1) SV2002000092A (es)
TN (1) TNSN00119A1 (es)
TR (1) TR200103472T2 (es)
UY (1) UY26177A1 (es)
WO (1) WO2000073303A1 (es)
ZA (1) ZA200109839B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551846A1 (en) * 2002-10-04 2005-07-13 Merck Sharp & Dohme Ltd. Azabicyclic spiroether derivatives as receptor antagonists
KR20070092993A (ko) * 2003-06-18 2007-09-14 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 결정형 xiv, lxxiii,lxxix, lxxx 및 lxxxvii, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법
US7371906B2 (en) 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DE69208877T2 (de) * 1991-05-31 1996-07-25 Pfizer Chinuclidinderivate
US5886009A (en) * 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

Also Published As

Publication number Publication date
PE20010155A1 (es) 2001-02-08
AU4424600A (en) 2000-12-18
HN2000000076A (es) 2001-02-02
EE200100655A (et) 2003-02-17
NO20015845D0 (no) 2001-11-30
OA11955A (en) 2006-04-13
IS6129A (is) 2001-10-26
HK1046407A1 (zh) 2003-01-10
HUP0201798A3 (en) 2002-10-28
BR0011125A (pt) 2002-02-19
JP2003501353A (ja) 2003-01-14
MXPA01012328A (es) 2002-07-30
NO20015845L (no) 2002-01-30
GT200000086A (es) 2001-11-21
AU767331B2 (en) 2003-11-06
EA200100982A1 (ru) 2002-06-27
HUP0201798A2 (en) 2002-09-28
CZ20014270A3 (cs) 2002-08-14
UY26177A1 (es) 2000-12-29
BG106139A (bg) 2002-05-31
EP1181289A1 (en) 2002-02-27
SV2002000092A (es) 2002-02-05
CR6513A (es) 2003-11-25
CA2372236A1 (en) 2000-12-07
CN1353712A (zh) 2002-06-12
AR029753A1 (es) 2003-07-16
NZ514762A (en) 2002-12-20
HRP20010884A2 (en) 2003-04-30
PA8496001A1 (es) 2002-07-30
SK17342001A3 (sk) 2002-10-08
EA004206B1 (ru) 2004-02-26
AP2001002350A0 (en) 2001-12-31
WO2000073303A1 (en) 2000-12-07
IL145952A0 (en) 2002-07-25
TR200103472T2 (tr) 2002-05-21
KR20020005055A (ko) 2002-01-16
PL352715A1 (en) 2003-09-08
CO5170468A1 (es) 2002-06-27
DZ3051A1 (fr) 2004-03-27
US6387925B1 (en) 2002-05-14
TNSN00119A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
AU6751301A (en) 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0202034A3 (en) Heterocyclic substituted aminoazacycles useful as central nervous system agents
HK1036623A1 (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
IL146410A0 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2] oct-3-yl)-(1so-propyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists
IL145952A0 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo [2.2.2.] oct-3-yl) - (5-iso-propyl-2-methoxybenzyl) - amine citrate as nk-1 receptor antagonists
PL351088A1 (en) Process for the preparation of substituted pyrimidines
HUP0102710A2 (hu) Új eljárás prosztaglandinvegyületek előállítására
HK1039334A1 (en) Process for preparing tricyclic compounds having antihistaminic activity
HUP9800689A3 (en) Nk-1 receptor antagonists for the treatment of delayed emesis
IL135809A0 (en) Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
TW441337U (en) Improved structure of shaking machine for drinks
AU7025800A (en) Process for the preparation of 1-methyl-3-carbomethoxy-4-(4'-fluorophenyl)-piperidine
TW503847U (en) Improved retainer structure for casters of machine
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
GB9906120D0 (en) Process for the preparation of new heterocyclic compounds
AU7542900A (en) Process for the preparation of paroxetine intermediate
SI1200414T1 (en) Process for the preparation of substituted pyrimidines
GB9814737D0 (en) Fibrinogen receptor antagonists